Today: 20 July 2026
Browse Category

LSE:GSK 30 July 2025 - 10 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc heads into the final month of 2025 near multi‑year highs, powered by a strong run of earnings beats, a revived oncology franchise and a looming change at the top of the company. As of 2 December 2025, the stock sits close to its 52‑week peak while analyst opinion remains broadly neutral and focused on whether the pipeline can deliver enough growth to meet GSK’s ambitious 2031 revenue targets. Hargreaves Lansdown+2Yahoo Finance+2
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK PLC Share Price: What to Know Before the London Market Opens on 17 November 2025

As London investors get ready for the opening bell on Monday, 17 November 2025, GSK plc is entering the week in a strong but finely balanced position: the shares sit close to their 52‑week highs, the company has just gone ex‑dividend, buybacks are running hard, guidance has been upgraded, key drugs have hit major regulatory milestones – and legacy Zantac litigation is easing but not gone.
16 November 2025
European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

European markets closed the first day of the week with small gains. The pan‑European STOXX 600 edged up 0.18% to 555.53 aa.com.tr. Germany’s DAX 40 barely budged to 23,745.06 aa.com.tr, while Britain’s FTSE 100 added 0.16% to 9,299.84 aa.com.tr. France’s CAC 40 rose 0.13% to 7,880.87. By contrast, Italy’s FTSE MIB and Spain’s IBEX 35 both fell about 0.22% on the day aa.com.tr. Across the Atlantic, U.S. stock futures were little changed, reflecting caution ahead of key U.S. developments.
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

On Monday, Europe’s stock markets built on last week’s Fed-inspired optimism. Investors cheered a mix of corporate news and the prospect of more US rate cuts. Britain’s FTSE 100 climbed roughly 0.5%, putting it near record highs, and the STOXX 600 closed about +0.2% reuters.com. France’s CAC 40 and Germany’s DAX each gained a few tenths of a percent reuters.com. Major indices in Southern Europe also edged up. Across sectors, the strongest gains were in healthcare and tech, offsetting weakness in commodity-linked areas and automakers.
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be that first line of defence,” said Dr. Adam Braunschweig of CUNY, who led the study gavi.org. The findings, published in Science Advances, mark an early proof-of-concept for broad-spectrum antivirals, though further work is needed to advance these candidates into animal and human trials. Experts note this approach could be game-changing in future pandemics, filling the gap while vaccines and virus-specific drugs are developed gavi.org.
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic reuters.com. The change marks a sharp departure from broad eligibility in previous years. Officials and experts voiced concern that narrowing access could sow confusion over insurance coverage and leave many younger adults unprotected reuters.com reuters.com. Notably, the FDA also rescinded emergency authorization for Pfizer’s vaccine in children under 5, effectively pausing toddler immunizations reuters.com. Medical societies pushed back – the Infectious Diseases Society of America announced it is working with other groups on independent COVID vaccine guidelines, expected in September reuters.com. The American Academy of Pediatrics even went against federal policy, recommending that all young children get vaccinated for COVID-19 reuters.com.
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

This 48-hour period brought a flurry of major developments in biotechnology, pharmaceuticals, medicine and public health worldwide – from game-changing clinical trial victories and regulatory decisions to urgent health policy actions and scientific breakthroughs. Below is a comprehensive roundup of the top news from August 10–11, 2025.
From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

Samsung Unveils Thinner Foldables: Samsung launched its latest foldable smartphones – the Galaxy Z Fold7 and Galaxy Z Flip7 – touting them as the thinnest, lightest iterations yet. The premium Galaxy Z Fold7 now starts at $1,999, while a new cheaper Flip7 FE comes in at $899 reuters.com. Both devices sport slimmer profiles to address past bulkiness reuters.com. Analysts say the refinements help Samsung fend off growing competition from Chinese rivals in the niche foldables market reuters.com. The company is even teasing a tri-foldable phone by year’s end reuters.com, signaling Samsung’s aggressive roadmap for foldable consumer electronics innovation.
Go toTop